Core Insights - Windtree Therapeutics, Inc. will present new positive topline results from the Phase 2b SEISMiC Extension Study of istaroxime for early cardiogenic shock during a virtual Investor Day on October 1, 2024 [1][2] - The presentation will include insights from Dr. Alexandre Mebazaa, a leading expert in cardiogenic shock and heart failure, and will feature a Q&A session [2] Company Overview - Windtree Therapeutics is a biotechnology company focused on developing innovative therapies for critical conditions, with a portfolio that includes istaroxime, a Phase 2 candidate for acute heart failure and cardiogenic shock [6] - Istaroxime is a first-in-class dual-mechanism therapy that enhances both systolic and diastolic cardiac function, improving myocardial contractility and facilitating myocardial relaxation [5][6] Clinical Development - Istaroxime has shown significant improvements in cardiac function and blood pressure in multiple Phase 2 trials without increasing heart rate or causing cardiac rhythm disturbances [5] - The company is advancing its clinical development programs, including preclinical SERCA2a activators for heart failure and precision aPKCi inhibitors for oncology applications [6]